Walden Biosciences has appointed Howard Mayer, M.D., former Executive VP of R&D at Ipsen, to its Board of Directors as the company approaches key clinical milestones.
Walden Biosciences has fully enrolled the second cohort in its Phase 2 basket study of WAL0921 for chronic kidney disease, targeting diabetic nephropathy.